Immune checkpoint inhibitors may be safe for patients with preexisting autoimmune disease

Abstract

Key Points The use of ICIs in patients with PADs is safe but requires close monitoring. For patients with stable PADs, minimal IS treatment is advised at the time of initiation of ICIs. Oncologists, rheumatologists, and other relevant specialists should collaborate to detect and manage irAEs among patients with PADs.